These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23140274)

  • 1. Cost-effectiveness of rituximab in follicular lymphoma.
    Johnston KM; Bolbocean C; Connors J; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
    Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
    Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
    Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
    Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
    Prica A; Chan K; Cheung M
    Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
    Deconinck E; Miadi-Fargier H; Pen CL; Brice P
    Pharmacoeconomics; 2010; 28(1):35-46. PubMed ID: 20014875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
    Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
    Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.
    Hayslip JW; Simpson KN
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):166-70. PubMed ID: 18650180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
    Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
    Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
    Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
    Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.
    Pink J; Lane S; Hughes DA
    Pharmacoeconomics; 2012 May; 30(5):413-29. PubMed ID: 22428718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
    Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy in follicular lymphoma.
    Michallet AS; Coiffier B; Salles G
    Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
    Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
    Greenhalgh J; Bagust A; Boland A; Blundell M; Oyee J; Beale S; Dundar Y; Hockenhull J; Proudlove C; Chu P
    Pharmacoeconomics; 2013 May; 31(5):403-13. PubMed ID: 23576017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.